Related Experiment Video
Updated: Feb 10, 2026

Modeling Stroke in Mice: Focal Cortical Lesions by Photothrombosis
Published on: May 6, 2021
Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European
Andrew D Blann1, Ron Pisters2, Gregory Y H Lip3
1University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom.
Edoxaban offers significant clinical benefits for patients with atrial fibrillation (AF) by reducing stroke, death, and major bleeding events. This anticoagulant provides a net clinical advantage over warfarin and no treatment, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Vitamin K antagonists like warfarin are underused in atrial fibrillation (AF) due to hemorrhage concerns.
- Non-vitamin K antagonist oral anticoagulants (NOACs) offer similar or greater efficacy with lower bleeding rates.
- The real-world application of edoxaban trial data in European AF populations remains unclear.
Purpose of the Study:
- To determine the net clinical benefit of edoxaban in reducing stroke, mortality, and hemorrhage risk.
- To model edoxaban's effectiveness in a European population at risk of stroke due to AF.
Main Methods:
- Modeled the treatment effect of edoxaban on thromboembolism, major bleeding, and death risks.
- Utilized data from the Euro Heart Survey for a real-world AF patient population.
- Extrapolated findings to the general European population.
Main Results:
- Edoxaban use in high-risk AF patients (CHA2DS2VASc ≥2) prevents 1 event (thromboembolism, major bleeding, or death) per 319 patients compared to warfarin.
- Edoxaban prevents 1 thromboembolism or death per 41 patients compared to no treatment.
- Annual modeling suggests edoxaban could prevent 19,400-30,300 thromboembolic events, major bleeds, and deaths in Europe.
Conclusions:
- Edoxaban use for thromboprophylaxis in AF, following guidelines, offers substantial benefits.
- Profound improvements in stroke, major bleeding, and mortality rates are suggested for European AF patients.
- Modeling indicates a significant net clinical benefit for edoxaban in AF management.
Related Concept Videos
Conservation of Small Populations
Benefits of Self-Esteem
Fischer Projections
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Newman Projections
The organic molecules rotate across the single bonds leading to numerous temporary three-dimensional structures of varying energy known as...
What is Population Genetics?

